Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 02/12 03:59:59 pm
89.44 USD   +2.38%
02/09 Wall Street cuts losses late to end tad lower
02/08 GILEAD SCIENCES : to Participate in Two Upcoming Investor Conference..
02/08 SANOFI : Appoints muzammil mansuri to executive committee and execut..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
02/11 GILEAD SCIENCES : Announces Promotion of Katie Watson to Executive Vice Presiden..
02/11 GILEAD SCIENCES : European Medicines Agency Validates Gilead's Type II Variation..
02/09 Wall Street cuts losses late to end tad lower
02/08 GILEAD SCIENCES : to Participate in Two Upcoming Investor Conferences
02/08 SANOFI : Appoints muzammil mansuri to executive committee and executive vice pre..
02/07 CELGENE, GILEAD SCIENCES SHARES COUL : Barron's
02/05 SANOFI : Muzammil Mansuri is Sanofi’s new Executive Committee member
02/04 GILEAD SCIENCES : Patent Issued for Process for Preparing Dronedarone and Salts ..
02/04 GILEAD SCIENCES : to Release Fourth Quarter and Full Year 2015 Financial Results..
02/04 GILEAD SCIENCES : What's on tap for La Verne this coming year
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials